Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
06 oct. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
24 sept. 2020 16h12 HE
|
Kiniksa Pharmaceuticals, Ltd.
- Virtual event to take place from 8:00 a.m. to 9:30 a.m. EDT - HAMILTON, Bermuda, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical...
Kiniksa Announces Upcoming Rilonacept Analyst Day
21 sept. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
15 sept. 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
09 sept. 2020 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare...
Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
31 août 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
04 août 2020 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday,...
Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
30 juil. 2020 07h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year – – Mavrilimumab...
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
21 juil. 2020 21h55 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A...
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
20 juil. 2020 16h07 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0...